Objectives. To compare the clinical presentation, response to therapy and outcome of thrombotic thrombocytopenic purpura (TTP) in an inception cohort of patients with and without SLE. Methods. Medical records of patients diagnosed with TTP at Singapore General Hospital between January 2003 and December 2007 were reviewed. Results. Ten idiopathic TTP (iTTP) and eight SLE-associated TTP (sTTP) patients were identified, with iTTP patients being older (mean 50.4 vs 34.5 yrs). Five iTTP patients were ANA positive but did not have any features of SLE. All sTTP patients had active SLE at TTP diagnosis and had more renal involvement than iTTP (87.5% vs 50%). The mean duration from the first symptom suggestive of TTP to diagnosis was 7.7 days and 19.5 days in iTTP and sTTP patients. All patients received high-dose corticosteroids. Cytotoxic and immunosuppressive drugs were used more commonly (87.5% vs 50%) and earlier (Day 2/3 vs after Day 7) in sTTP patients. Vincristine was the drug of choice in iTTP and cyclophosphamide in sTTP. Three SLE patients received rituximab. Mortality for iTTP and sTTP was 50% (95% CI 19%, 81%) and 62.5% (95% CI 29%, 96%), respectively. The mean (S.D.) time to complete remission was 31.3 (AE 26.4) days in sTTP (n ¼ 3) and 16.8 (AE 6.1) days in iTTP (n ¼ 5). Conclusion. Despite early and more aggressive therapy in sTTP, mortality was higher and the time to complete remission were longer, suggesting that sTTP is more severe. The tempo of development of TTP in SLE patients was slower.
Introduction
Thrombotic thrombocytopenic purpura (TTP) was first described by Moschowitz in 1924 as a syndrome characterized by a diagnostic pentad of severe thrombocytopenia (<50 000/l), microangiopathic haemolytic anaemia (MAHA), neurological symptoms, renal impairment and fever [1] . It has a very high mortality if not treated and even with current treatment strategies, there is still a significant mortality of 10-30% in patients with idiopathic TTP (iTTP) [2] .
Although the majority of cases of TTP are idiopathic, it is known to occur in association with malignancies, infections, pregnancy, drugs and CTDs [3] . The iTTP has an estimated incidence of 4.46 cases per million population per year and occurs in 2-3% of SLE patients [4] . Diagnostic uncertainty may arise in differentiating TTP from haemolytic-uraemic syndrome (HUS), which is defined as the triad of acute renal insufficiency, MAHA and thrombocytopenia. If severe renal failure is the predominant feature at presentation, HUS should be considered, but precise clinical distinction between TTP and HUS is not always possible. For this reason, the term TTP-HUS is at times used to describe these patients [5] [6] [7] . Recently two new 'subsets' known as microvascular and microangiopathic anti-phospholipid-associated syndromes (MAPS) have also been proposed for thrombotic microangiopathy accompanied by aPLs [8] .
The association between TTP and SLE has been well recognized in clinical and histological reports. Devinski et al. [9] reviewed medical and autopsy records of 50 consecutive SLE patients and noted pathological changes consistent with TTP in 14% of the patients, all of whom had clinical evidence of TTP in retrospect. However, it can be difficult to diagnose TTP when it presents simultaneously with an SLE flare due to overlapping clinical features. Further, it has been our clinical impression that the use of corticosteroids and immunosuppressants in SLE patients may slow the usually rapid tempo of development of clinical features of TTP, further delaying the diagnosis of TTP in SLE patients, especially when patients do not yet fulfil the diagnostic pentad of TTP. In SLE, careful laboratory examination especially for the presence of significant number of schistocytes (fragmented erythrocytes) in the peripheral blood film (PBF) should raise the suspicion of TTP in a patient with renal and central nervous system (CNS) dysfunction. In practice, a diagnosis of TTP may be made in the presence of MAHA, a raised lactate dehydrogenase (LDH) without any other cause and a platelet count of <100 000 l [10, 11] . Such patients are often treated with plasmapheresis and immunosuppression to avoid the near 100% mortality associated with untreated TTP [12] . However, the outcome of such therapies in TTP patients with SLE has not been well studied.
Given the difficulties of diagnosing TTP in SLE and the lack of comparative data on the presentation and outcome of therapy in iTTP vs SLE-related TTP, this study sought to compare the presentation, response to therapy and outcome in an inception cohort of TTP patients with and without SLE. By further characterizing the clinical presentation of TTP in SLE vs non-SLE patients, we hoped to identify features that would allow an earlier diagnosis of TTP in patients with SLE. By comparing the response with therapy in these patients, we hoped to provide information on the relative efficacy of plasmapheresis and immunosuppression in such patients.
Materials and methods
Medical records of patients diagnosed with TTP who underwent plasmapheresis in Singapore General Hospital (a major tertiary referral centre in Singapore) over a 5-yr period between January 2003 and December 2007 were identified from hospital databases in this Institutional Review Board approved study. The diagnosis of TTP was based on Moschowitz criteria, which includes a pentad of severe thrombocytopenia (<50 000 l), MAHA, neurological symptoms, renal impairment and fever [1] . The iTTP was defined as TTP occurring in patients with no apparent pre-existing disease. TTP related to organ transplantation, malignancy, HIV infection and drugs was excluded. SLE was diagnosed based on the revised 1997 ACR diagnostic criteria [13] . Demographic, clinical and immunological features of SLE patients were extracted from medical records using a standardized, pre-tested data collection form. The SLEDAI score was calculated for each SLE patient at the onset of TTP. The data obtained were compared between patients with iTTP and SLE-associated TTP (sTTP).
The definition of complete remission (CR) and refractory TTP was based on British Society of Haematology guidelines [10] . Complete remission was defined as normal neurological status, platelet count and LDH with a rising haemoglobin. Refractory disease or resistance to plasmapheresis was defined as persistent thrombocytopenia (platelet <150 000 l) or LDH elevation after a total of seven daily plasma exchanges.
Results

Patient characteristics
An inception cohort of 10 patients with iTTP and 8 patients with sTTP were identified in the 5-yr period from January 2003 to December 2007. Drugs that may induce TTP, such as antineoplastics, cyclosporin, tacrolimus and IFN were not used prior to onset of TTP in any of these patients. Patient characteristics are shown in Table 1 . The iTTP patients were older than sTTP patients, with a female preponderance noted in both the groups. Among sTTP patients, four (50%) fulfilled all five criteria, three (37.5%) fulfilled four criteria and one(12.5%) fulfilled three criteria for the diagnosis of TTP. Among iTTP patients, four (40%) patients had all five criteria, three (30%) had four criteria, two fulfilled three criteria and one had two criteria. All patients had MAHA and thrombocytopenia which adheres to the current understanding that only these two features without any apparent alternative aetiology are required to establish the diagnosis and initiate plasma exchange [14] . All patients were started on plasmapharesis within 24 h of diagnosis and co-managed with our haematology colleagues. Seven of eight (87.5%) sTTP patients had renal involvement compared with 5/10 (50%) iTTP patients. One patient had a renal biopsy that showed Class IV lupus nephritis without any histological features of TTP. This renal biopsy was performed six days after the diagnosis of SLE and the patient was already on therapy with high-dose corticosteroids (intravenous hydrocortisone 100 mg every 6 h). TTP was subsequently diagnosed when worsening thrombocytopenia and MAHA developed 12 days after the date of the renal biopsy, and thus may not have captured the TTP changes in the histology.
The mean duration from the first symptom suggestive of TTP to diagnosis of MAHA (thus a diagnosis of TTP) was 7.7 days in iTTP and 19.5 days in sTTP patients. Two of the sTTP patients (Patients 6 and 8) were on high-dose hydrocortisone, whereas another two patients (Patients 1 and 3) were on low-dose oral prednisolone prior to diagnosis of TTP. Two patients (Patients 3 and 8) were on mycophenolate mofetil (MMF) for 5 days and 11 days before TTP diagnosis. Patient 2 was on HCQ for many years. Five patients in the iTTP group had a positive ANA but did not have clinical features suggestive of any CTD at diagnosis of TTP. Among the surviving ANA-positive iTTP patients (n ¼ 3), no patient developed a defined CTD after a mean follow-up of 21.3 months (range 4-48 months). Table 2 summarizes the baseline serology and disease activity of sTTP patients. Seven of eight patients had a SLEDAI score exceeding 10, with one patient having a SLEDAI score of 45. Serum complement levels were low with the exception of one patient, indicating active disease at the time of diagnosis of TTP. Two patients (25%) presented with TTP at the time of diagnosis of SLE, while the duration of SLE prior to onset of TTP in the remaining six patients (75%) ranged from 18 days to 24 yrs. Table 3 shows the treatment and outcome of patients in both groups and Table 4 summarizes these in detail for each individual patient. The proportion of patients who were refractory to plasmapheresis was similar in both the groups. Use of cytotoxics, immunosuppressives and biological agents and mortality were higher in the sTTP group. Mortality in the iTTP vs sTTP groups was 50% (95% CI 19%, 81%) and 62.5% (95% CI 29%, 96%), respectively, with causes of death as listed in Table 4 . All patients received high-dose corticosteroids except for one patient in the iTTP group; this patient received corticosteroids when she relapsed 1 month after the initial remission. Only two (20%) patients in the iTTP group received pulse methylprednisolone (given daily for 3 days) compared with five (62.5%) in the SLE group. Cytotoxic and immunosuppressive agents were introduced earlier for sTTP (as early as the second or third day of therapy) as compared with the iTTP group where these agents were generally used after 7 days. Vincristine was the cytotoxic of choice in the iTTP group, and cyclophosphamide (CYC) in the sTTP group. Rituximab (375 mg/m 2 weekly) was used in three SLE patients: two responded and were able to cease plasmapheresis after two and seven doses, respectively, but the response in third patient was not assessable as she perished from pulmonary haemorrhage after one dose. The second patient (Patient 7) who responded relapsed after 3 weeks. She then responded partially to four further doses of rituximab but perished from neutropenic sepsis after an autologous peripheral blood stem cell transplant (PBSCT). Complete remission was achieved in 3/8 (37.5%) patients in SLE group (range 7-68 days) and 5/10 (50%) patients in the iTTP group (range 5-22 days) with the mean (S.
Treatment and outcome
D.) time to complete remission being 31.3 days (26.4) for sTTP and 16.8 days (6.1) for iTTP patients. Table 5 shows other possible factors that could have contributed to the mortality in both groups of patients, including the number of TTP criteria fulfilled and presence of renal impairment.
Discussion
In this retrospective cohort study comparing an inception cohort of TTP patients with and without SLE, we found that the tempo of development of the classic features of TTP (proposed by Moschowitz) was slower in sTTP than iTTP patients. Although 50% of the iTTP patients had one or more positive autoantibodies at diagnosis of TTP, none of the survivors in the iTTP cohort developed a CTD during follow-up, while all sTTP patients had active SLE at the time of TTP. Importantly, the response to therapy appeared to be poorer and mortality higher in sTTP as compared with iTTP patients. To the best of our knowledge, this is the first study comparing an inception cohort of TTP patients with and without SLE, and the result of this study suggest several learning points that are discussed below.
First, the slower tempo of presentation of TTP in patients with SLE vs idiopathic TTP (19.5 days vs 7.7 days) suggests that clinicians need to have a high index of suspicion for TTP in SLE patients presenting with thrombocytopenia, renal and CNS dysfunction. This slower tempo may be due to one or a combination of factors. The prior use of corticosteroids and immunosuppresives in SLE (Patients 1, 3, 6 and 8) may have slowed the tempo of development of TTP by partially suppressing the immune mechanisms that could trigger TTP. Alternatively, investigations to confirm MAHA may have been performed later in the disease course when an SLE patient with CNS and/or renal involvement failed to respond to therapy (thus raising the possibility of TTP). However, this was not the case for Patients 1, 2, 6 and 8, where PBFs were performed early in the disease course but initially did not show or only showed occasional fragmented cells. Serial PBFs were performed and the increasing magnitude of fragmented cells confirmed the diagnosis of TTP. Third, given the overlap in clinical features between SLE and TTP, the presumed first symptom of TTP could be due to SLE rather than TTP and vice versa.
Recent evidence suggests that patients with iTTP have deficiency in a protease named ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type 1 motif), which normally degrades large von Willebrand factor (vWF) multimers into smaller forms in the peripheral circulation [15] [16] [17] . This results in accumulation of unusually large vWF multimers that are 
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responsible for the abnormal platelet aggregation seen in TTP. In most cases, severe ADAMTS-13 deficiency is secondary to the development of anti-ADAMTS-13 auto-antibodies [16, 18] . This raises the possibility of using low ADAMST-13 activity or presence of auto-antibodies to ADAMTS-13 in making an early diagnosis of TTP in SLE patients. However, although auto-antibodies against ADAMTS-13 have been reported in patients with SLE and TTP [14] , 18% of the patients with SLE or APS without TTP also have detectable levels of these antibodies [19] , which reduce the diagnostic value of ADAMTS-13 levels in making an early diagnosis of TTP in patients with SLE [20] . Thus, the diagnostic pentad remains central to the diagnosis of TTP in SLE patients. Given that the tempo of development may be slower, a high index of suspicion is necessary as delays in diagnosis may carry significant prognostic and therapeutic implications. We would therefore suggest performing a routine screen for TTP in SLE patients with active renal and/or CNS involvement, especially if both organ systems are involved or if they are refractory to standard therapy. Even if the initial PBF does not show schistocytes, serial PBFs should be performed if the clinical suspicion is high as MAHA may develop later as illustrated by Patients 1, 2, 6 and 8 in this series.
Second, none of our cohort with iTTP and positive autoantibodies developed SLE during a mean follow-up period of 21.3 months. This observation further extends the limited literature describing the prevalence of auto-antibodies in patients with iTTP and progression to SLE. A study by Coppo et al. [21] showed that in a cohort of 31 patients with TTP, 22 (71%) patients had a positive ANA and 3 (9.7%) had a positive antids-DNA at the time of diagnosis; one fulfilled diagnostic criteria for SLE and one patient developed lupus-like disease during follow-up. ANA was positive only in patients with severe ADAMTS-13 deficiency, as no patient with detectable ADAMTS-13 activity displayed such antibodies, yielding a specificity and positive predictive value of 100% for ANA in predicting severe ADAMTS-13 deficiency in TTP [21] . In a review by Musio et al. [22] of 40 reported cases of TTP in association with SLE, 15% developed SLE after diagnosis of TTP, 12% developed SLE concurrently and 73% developed TTP after the diagnosis of SLE. The diagnosis of SLE was made from 2 weeks to 9 yrs after that of TTP, with a median of 2 yrs. Only two of the six patients had a positive ANA at TTP diagnosis and the other four patients presented with SLE after a mean of 5 yrs.
Third, the response to therapy appeared to be poorer and mortality higher in sTTP as compared with iTTP patients. This is despite more aggressive therapy for sTTP because of multi-organ SLE involvement (especially severe renal involvement) which required early and aggressive immunosuppression. All sTTP and most iTTP subjects received high-dose corticosteroids and all received plasmapheresis, while cytotoxics and immunosuppressives were given in 50% of iTTP and 87.5% of sTTP patients. The mean time to complete remission for surviving patients was also longer in sTTP patients [31.3 days (S.D. AE 26.4) vs 16.8 days (S.D. AE 6.1)], suggesting a more refractory and severe disease. There are several possible reasons for the higher mortality in sTTP patients. First, the presence of two potentially life-threatening conditions (i.e. SLE and TTP) in the same patient could increase mortality, as suggested by Hamasaki et al. [23] . The presence of MAHA in SLE patients may also indicate a more severe form of SLE with a much worse prognosis. Second, more sTTP patients were refractory to plasmapheresis. It is well known that such refractory patients have a poorer prognosis [24, 25] . Third, the slower tempo of development of TTP in sTTP patients may have resulted in plasmapheresis being initiated later in the disease process, which has been associated with treatment failure [26] . Other possible prognostic factors that could have contributed to the mortality in both groups are shown in Table 5 . The higher the number of Moschowitz criteria that a patient fulfilled and the presence of renal impairment seemed to contribute to a higher mortality. However, it was difficult to assess the effect of methylprednisolone and immunoglobulins on the outcome as the number of patients involved were very small.
Given the poorer response to therapy and increased mortality in sTTP patients with current therapies, new therapeutic modalities are urgently needed for such patients. Our results suggest that there may be a role for rituximab (a monoclonal anti-CD20 antibody), given that in two sTTP patients refractory to plasmapheresis who had an adequate course of rituximab, one went into complete remission while another achieved partial remission. Recently, a case of successful use of rituximab in recalcitrant TTP secondary to SLE was reported, in which the patient underwent remission after 4 weekly doses of rituximab [27] . A systemic review by Arnold et al. [28] showed that up to April 2006, there were 19 reports (313 patients) of the efficacy of rituximab in iTTP. Rituximab resulted in complete response (platelet count > 150 Â 10 9 cells/l) in 43.6% of the patients (95% CI 29.5%, 57.7%) and an overall response (platelet response >50 Â 10 9 cells/l) in 62.5% (95% CI 52.6%, 72.5%). Most were refractory to multiple treatments before receiving rituximab [28] . Responses lasted from 2 to 48 months. This is buttressed by evidence from the largest case series published to date (n ¼ 25) that treating acute refractory TTP patients with rituximab as early as 7 days after admission will induce a rapid and high rate of remission and is associated with very few short-term side effects [29] . The ongoing Transfusion Medicine/Hemostasis (TMH) Clinical Trials Network randomized, a clinical trial to determine the efficacy of rituximab in addition to standard treatment of TTP with plasma exchange and steroids will hopefully provide a definitive answer regarding the efficacy of rituximab in iTTP [30] .
We recognize several limitations of this study. First, the retrospective nature of data collection is not as rigorous as in a prospective study; however, this is unlikely to have affected the major findings reported above. Second, the relatively small number of subjects provides limited statistical power for comparisons. However, given the rarity of TTP, our results are interesting and are strengthened as they are coming from a single institution, and by the fact that management of sTTP patients incorporated input from the haematology service (who managed iTTP patients).
Conclusions
Despite the early and more aggressive therapy in SLE patients, mortality was higher and the time to complete remission was longer compared with idiopathic TTP, suggesting a more refractory and severe disease. The tempo of development of TTP in SLE patients was also slower, highlighting the need for a high index of clinical suspicion of TTP in these patients with renal and CNS involvement. These comparative data shed light on the similarities and differences of TTP in patients with and without SLE, and highlight the pressing need for newer modalities of treatment to improve the outcome of patients with SLE and TTP.
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